1. Home
  2. ADVM vs GGT Comparison

ADVM vs GGT Comparison

Compare ADVM & GGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • GGT
  • Stock Information
  • Founded
  • ADVM 2006
  • GGT 1994
  • Country
  • ADVM United States
  • GGT United States
  • Employees
  • ADVM N/A
  • GGT N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • GGT Trusts Except Educational Religious and Charitable
  • Sector
  • ADVM Health Care
  • GGT Finance
  • Exchange
  • ADVM Nasdaq
  • GGT Nasdaq
  • Market Cap
  • ADVM 119.6M
  • GGT 136.5M
  • IPO Year
  • ADVM 2014
  • GGT N/A
  • Fundamental
  • Price
  • ADVM $4.74
  • GGT $4.76
  • Analyst Decision
  • ADVM Strong Buy
  • GGT
  • Analyst Count
  • ADVM 6
  • GGT 0
  • Target Price
  • ADVM $27.83
  • GGT N/A
  • AVG Volume (30 Days)
  • ADVM 226.5K
  • GGT 59.7K
  • Earning Date
  • ADVM 11-04-2024
  • GGT 01-01-0001
  • Dividend Yield
  • ADVM N/A
  • GGT 15.56%
  • EPS Growth
  • ADVM N/A
  • GGT N/A
  • EPS
  • ADVM N/A
  • GGT 0.83
  • Revenue
  • ADVM $1,000,000.00
  • GGT N/A
  • Revenue This Year
  • ADVM N/A
  • GGT N/A
  • Revenue Next Year
  • ADVM $1,342.84
  • GGT N/A
  • P/E Ratio
  • ADVM N/A
  • GGT $6.90
  • Revenue Growth
  • ADVM N/A
  • GGT N/A
  • 52 Week Low
  • ADVM $4.59
  • GGT $4.32
  • 52 Week High
  • ADVM $29.70
  • GGT $7.00
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 26.02
  • GGT 43.62
  • Support Level
  • ADVM $4.59
  • GGT $4.61
  • Resistance Level
  • ADVM $4.89
  • GGT $4.93
  • Average True Range (ATR)
  • ADVM 0.31
  • GGT 0.09
  • MACD
  • ADVM -0.06
  • GGT -0.03
  • Stochastic Oscillator
  • ADVM 9.80
  • GGT 28.85

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

About GGT Gabelli Multi-Media Trust Inc. (The)

Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.

Share on Social Networks: